Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo, Aussie Biota Join To Market Flu Drug

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo and Australia's Biota have signed an agreement for the Japanese company to produce and market Biota's influenza neuraminidase inhibitor in Japan. At the center of the agreement is molecule CS-8958, which the two companies co-developed. Actual marketing depends on a Phase III trial still being conducted and then government approval. In the deal, whose terms were not disclosed, the two firms are to share in non-Japan licensing arrangements. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel